We are live on
!
Find out more
CMMB
Chemomab Therapeutics
CMMB
CMMB
10 hedge funds and large institutions have $1.03M invested in Chemomab Therapeutics in 2025 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 6 reducing their positions, and 5 closing their positions.
New
Increased
Maintained
Reduced
Closed
1.94% more ownership
Funds ownership: 5.61% → 7.54% (+1.9%)
29% less funds holding
Funds holding: 14 → 10 (-4)
67% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 6
79% less capital invested
Capital invested by funds: $4.91M → $1.03M (-$3.88M)
80% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 5
Holders
10
Holders Change
-4
Holders Change %
-28.57%
% of All Funds
0.13%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
2
Reduced
6
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$111K |
| 2 |
Jane Street
New York
|
+$60.4K |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
+$8.39K |
Top Sellers
| 1 |
Morgan Stanley
New York
|
-$1.16M |
| 2 |
O
OrbiMed
New York
|
-$1.09M |
| 3 |
YLHM
Yelin Lapidot Holdings Management
Tel Aviv,
Israel
|
-$671K |
| 4 |
KPWS
Kestra Private Wealth Services
Austin,
Texas
|
-$36.2K |
| 5 |
BFM
Boothbay Fund Management
New York
|
-$30.4K |